Pseudoprogression of glioblastoma after chemo- and radiation therapy: Diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival

Radiology

Volumn 266, Issue 3, 2013, Pages 842-852

  Gahramanov, Seymur ^a   Muldoon, Leslie L ^a   Varallyay, Csanad G ^a   Li, Xin ^b   Kraemer, Dale F ^d   Fu, Rongwei ^a,b   Hamilton, Bronwyn E ^a   Rooney, William D ^b   Neuwelt, Edward A ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FERUMOXYTOL; GADOTERIDOL; TEMOZOLOMIDE;

ARTICLE; BRAIN BLOOD VOLUME; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYNAMIC SUSCEPTIBILITY WEIGHTED CONTRAST ENHANCED PERFUSION MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; WHOLE BODY MRI;

ADULT; AGED; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CONTRAST MEDIA; FEMALE; FERUMOXYTOL; GADOLINIUM; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84874310719     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111472     Document Type: Article

References (44)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10): 987-996.
2. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 2009;94(1): 97-101.
3. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63(3): 535-537.
4. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26(13): 2192-2197.
5. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5): 453-461.
6. Tofilon PJ, Fike Jr. The radioresponse of the central nervous system: a dynamic process. Radiat Res 2000;153(4): 357-370.
7. Wong CS, Van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 2004;4(5): 273-284.
8. Nordal RA, Nagy A, Pintilie M, Wong CS. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 2004;10(10): 3342-3353.
9. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-oncol 2008;10(3): 361-367.
10. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191(1): 41-51.
11. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211(3): 791-798.
12. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171(6): 1479-1486.
13. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrastenhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25(2): 214-221.
14. Cao Y, Tsien CI, Nagesh V, et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006;64(3): 876-885.
15. Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusionweighted MR imaging predict malignant transformation? Radiology 2008;247(1): 170-178.
16. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrastenhanced perfusion MR imaging. Radiology 2008;247(2): 490-498.
17. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19(5): 546-554.
18. Barajas RF Jr, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility- weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253(2): 486-496.
19. Hoefnagels FW, Lagerwaard FJ, Sanchez E, et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol 2009;256(6): 878-887.
20. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30(3): 552-558.
21. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrastenhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011;79(2): 514-523.
22. Hu LS, Eschbacher JM, Dueck AC, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 2012;33(1): 69-76.
23. Sorensen AG. Perfusion MR imaging: moving forward. Radiology 2008;249(2): 416-417.
24. Neuwelt EA, Várallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007;60(4): 601-611; discussion 611-612.
25. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009;29(4): 853-860.
26. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010;30(1): 15-35.
27. Neuwelt EA, Hamilton BE, Varallyay CG, et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009;75(5): 465-474.
28. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14(2): 249-265.
29. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 1996;36(5): 715-725.
30. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27(4): 859-867.
31. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993;189(1): 233-238.
32. Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004;15(5): 279-289.
33. Heiland S, Benner T, Debus J, Rempp K, Reith W, Sartor K. Simultaneous assessment of cerebral hemodynamics and contrast agent uptake in lesions with disrupted blood-brainbarrier. Magn Reson Imaging 1999;17(1): 21-27.
34. Uematsu H, Maeda M. Double-echo perfusion- weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006;16(1): 180-186.
35. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrastenhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249(2): 601-613.
36. Hu LS, Baxter LC, Pinnaduwage DS, et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrastenhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010;31(1): 40-48.
37. Gahramanov SML, Muldoon LL, Li X, Neuwelt EA. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. Radiology 2011;261(3): 796-804.
38. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7): 1277-1280.
39. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3): 205-216.
40. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11): 1963-1972.
41. Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010;256(2): 575-584.
42. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113(2): 405-410.
43. Mason WP, Maestro RD, Eisenstat D, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 2007;14(3): 110-117.
44. Roldán GB, Scott JN, McIntyre JB, et al. Population- based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 2009;36(5): 617-622.